CXCR2 antagonist
Showing 1 - 25 of 5,291
Metastatic Castration Resistant Prostate Cancer Trial in Switzerland, United Kingdom (AZD5069, Enzalutamide 40 MG)
Active, not recruiting
- Metastatic Castration Resistant Prostate Cancer
- AZD5069
- Enzalutamide 40 MG
-
Bellinzona, Switzerland
- +3 more
Mar 18, 2022
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7 Trial in
Active, not recruiting
- Metastatic Pancreatic Adenocarcinoma
- +2 more
- CXCR4 Antagonist BL-8040
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Feb 9, 2022
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 Trial in Houston
Active, not recruiting
- Metastatic Melanoma
- +2 more
- Aldesleukin
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
SMART Protocol vs Antagonist Protocol in IVF
Active, not recruiting
- Diminished Ovarian Reserve
-
Montreal, Quebec, CanadaClinique Ovo
Dec 22, 2022
Hiv Trial in Philadelphia (Autologous CD4 T-Cells)
Completed
- Hiv
- Autologous CD4 T-Cells
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania
Nov 13, 2022
Healthy Trial in Madison (Selpercatinib, Ranitidine, Omeprazole)
Completed
- Healthy
- Selpercatinib
- +2 more
-
Madison, WisconsinCovance Clinical Research Unit, Inc.
Jan 12, 2023
Fibrolamellar Hepatocellular Carcinoma Trial in Baltimore (Durvalumab, DRP-104)
Not yet recruiting
- Fibrolamellar Hepatocellular Carcinoma
-
Baltimore, MarylandJohns Hopkins SKCCC
Aug 30, 2023
Waldenstrom's Macroglobulinemia Trial in Boston (Ulocuplumab, Ibrutinib)
Active, not recruiting
- Waldenstrom's Macroglobulinemia
-
Boston, MassachusettsDana Farber Cancer Institute
Jun 20, 2022
Safety Issues, Pain, Pancreas Fibrosis Trial in Washington (Proglumide, Placebo)
Recruiting
- Safety Issues
- +2 more
- Proglumide
- Placebo
-
Washington, District of ColumbiaGeorgetown University
Dec 1, 2022
Renal Cell Carcinoma Trial in Houston (Ipilimumab, Nivolumab, Ciforadenant)
Not yet recruiting
- Renal Cell Carcinoma
- Ipilimumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 11, 2022
in Vitro Fertilization, Poor Responder Trial in Toronto (metoclopramide)
Withdrawn
- in Vitro Fertilization
- Poor Responder
-
Toronto, Ontario, CanadaMount Sinai Hospital
Apr 7, 2022
Blood Flow Trial in Copenhagen (GIPR antagonist / study tool, GLP-2R antagonist / study tool, Placebo)
Recruiting
- Blood Flow
- GIPR antagonist / study tool
- +2 more
-
Copenhagen, DenmarkRigshospitalet
Nov 2, 2022
Spinal Cord Injuries, Myelopathy Trial in Cambridge (Istradefylline, low oxygen therapy)
Not yet recruiting
- Spinal Cord Injuries
- Myelopathy
- Istradefylline
- low oxygen therapy
-
Cambridge, MassachusettsSpaulding Rehabilitation Hospital
Jun 24, 2022
COVID-19, SARS-CoV2 Infection Trial in India (Candesartan Cilexetil, Repagermanium, Candesartan Placebo)
Recruiting
- COVID-19
- SARS-CoV2 Infection
- Candesartan Cilexetil
- +3 more
-
Guntur, India
- +4 more
Mar 13, 2022
Infertility Trial (10000 IU hCG (Choriomon5000 IU; IBSA), Triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring))
Not yet recruiting
- Infertility
- 10000 IU hCG (Choriomon5000 IU; IBSA)
- Triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring)
- (no location specified)
May 27, 2022
Ovarian Stimulation Trial in Shibin Al Kawm (Letrozole 2.5mg tablet)
Recruiting
- Ovarian Stimulation
- Letrozole 2.5mg tablet
-
Shibīn Al Kawm, Menoufia, EgyptMenoufia University hospital
Dec 8, 2021
Type 2 Diabetes, Glucose Tolerance Impaired, Insulin Sensitivity Trial in San Antonio (REMD-477, Placebo Subcutaneous injection)
Recruiting
- Type 2 Diabetes
- +2 more
- REMD-477
- Placebo Subcutaneous injection
-
San Antonio, TexasTexas Diabetes Institute
Dec 22, 2021
Exercise, Histamine Trial in Ghent (Placebo: Placebo + exercise training., H1 blockade: H1 receptor antagonist + exercise
Active, not recruiting
- Exercise
- Histamine
- Placebo: Placebo + exercise training.
- +2 more
-
Ghent, Oost-Vlaanderen, BelgiumDepartment of movement and sports sciences, Ghent University, Be
Nov 8, 2022
Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for
Active, not recruiting
- Heavy Menstrual Bleeding
- Fibroid Uterus
- Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure
- Elagolix Oral Product
-
Washington, District of ColumbiaMedStar Washington Hospital Center
Apr 29, 2022
Chronic Kidney Diseases Trial in Worldwide (Zibotentan, Dapagliflozin, Placebo)
Enrolling by invitation
- Chronic Kidney Diseases
- Zibotentan
- +3 more
-
Aurora, Colorado
- +5 more
Oct 18, 2022
Neuroendocrine Neoplasia's (NENs), Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) Trial in Basel (161Tb-DOTA-LM3,
Not yet recruiting
- Neuroendocrine Neoplasia's (NENs)
- Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
-
Basel, SwitzerlandDivision of Nuclear Medicine, University Hospital Basel
Apr 27, 2022
In-stent Restenosis Trial in Beijing (Colchicine, Prednisone, Aspirin)
Not yet recruiting
- In-stent Restenosis
- Colchicine
- +4 more
-
Beijing, Beijing, ChinaFuwai Hospital
Oct 15, 2023
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma Trial in Baltimore (Stereotactic Body
Recruiting
- Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
- Pancreatic Ductal Adenocarcinoma
- Stereotactic Body Radiation (SBRT)
- +3 more
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center
Jan 28, 2022
Pancreatitis, Acute Trial in Denmark, Sweden (Placebo treatment, Naldemedine 0.2 MG Oral Tablet)
Recruiting
- Pancreatitis, Acute
- Placebo treatment
- Naldemedine 0.2 MG Oral Tablet
-
Aalborg, Jutland, Denmark
- +4 more
Mar 7, 2022